• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PEB
Click for more information
6.13% 17.3¢

Pacific Edge Limited Ordinary Shares

watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
PEB
Ann: SPH Notice - FirstCape Group Limited 		20/09/24 0 71
20/09/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  71 
PEB
Ann: AUA Micro-Hematuria Guideline and Medicare Timelines 		13/09/24 0 182
13/09/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  182 
PEB
Ann: Pacific Edge Chairman Delays Retirement 		05/09/24 0 134
05/09/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  134 
PEB
Ann: Notice of Annual Shareholders Meeting 		15/08/24 0 165
15/08/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  165 
PEB
Ann: Novitas Releases New Draft LCD 		29/07/24 10 2.6K
29/07/24 Last post  Sloan Comments Created with Sketch.  10  Views Created with Sketch.  2.6K 
PEB
Ann: Novitas Confirms Medicare Coverage Review Extension 		29/07/24 0 173
29/07/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  173 
PEB
Ann: Medicare Coverage Determination Still Under Review 		26/07/24 0 176
26/07/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  176 
PEB
Ann: Director Nomination Closing Date 		16/07/24 0 141
16/07/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  141 

See All Discussions arrow Created with Sketch.

Featured News

NEWS Breakthrough FDA response clears path for OA phase 3 trial – major milestone achieved!
right-arrow Created with Sketch.
NEWS $11.1M capital raise secured – CEO leads $1M push to fast-track alzheimers trial
right-arrow Created with Sketch.
EBR $50M capital raise to scale EBR’s WiSE® System – FDA approval expected in 2025
right-arrow Created with Sketch.

(20min delay)
Last
17.3¢ 		Change
0.010(6.13%) 		Mkt cap ! n/a
Open High Low Value Volume
16.4¢ 18.0¢ 16.4¢ $697.1K 4.043M

Buyers (Bids)

No. Vol. Price($)
0 125689 17.1¢
 

Sellers (Offers)

Price($) Vol. No.
17.3¢ 61762 0
Last trade - 12.59pm 20/09/2024 (20 minute delay) ?
PEB (NZSX) Chart

Top Stories

Westar wraps up field campaign at Mindoolah after divesting non-core assets ahead of 2025

Westar Resources (ASX:WSR) has wrapped up a field campaign on-site its Mindoolah Mining Centre project in WA.
Catalina Resources kicks off aircore drilling at Laverton project on the hunt for gold, REEs Catalina Resources has confirmed its latest drill run has kicked off on-site its Laverton Project in Western Australia's Northern Goldfields.
Week 38 Wrap: US markets panic at 50bp cut; ALS’s minerals revenue  slowdown; RBA path unclear Well, it finally happened – the US Fed cut interest rates this week, and we got a double dose: a whole -50bps knocked off.
Sandfire's latest drill run extends known polymetal mineralisation at the Sesmarias Prospect Sandfire Limited (ASX:SFR) has posted evidence of extended mineralisation at its Portugese Sesmarias Prospect.
Drilling shows continuous Cu mineralisation at Whundo for Greentech Greentech Metals Ltd has rolled out an extensive drilling program at the Whundo copper-zinc project 40 kilometres from Karratha

Featured News

EBR $50M capital raise to scale EBR’s WiSE® System – FDA approval expected in 2025
right-arrow Created with Sketch.
NEWS $11.1M capital raise secured – CEO leads $1M push to fast-track alzheimers trial
right-arrow Created with Sketch.
NEWS Breakthrough FDA response clears path for OA phase 3 trial – major milestone achieved!
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.